- SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models - - PDX models were...
- Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models - VANCOUVER, Nov. 13, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq:...
- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 - VANCOUVER, Nov. 8, 2018 /CNW/ - Sierra...
View all news releases
Target Therapeutics for Hematology & Oncology - Q4 2018
View All Presentations
Date: November 14, 2018 Time: 5:20 pm GMT Location: London UK
View all events and webcasts
James Smith, Vice President Corporate Affairs investors@sierraoncology.com
Sign up for investor alerts
